Cancer Information Service (CIS) inquiries about cancer prevention and screening are an important opportunity to educate callers about primary or secondary cancer prevention, facilitate their decision-making, and, where appropriate, encourage action. An evaluation was conducted to assess whether these callers' information needs are being satisfied and to determine if the information provided facilitates decisionmaking and subsequent risk reduction actions. A random sample of 2,489 callers was surveyed during a 5-week period, 3 to 6 weeks after their initial call to CIS; prevention or screening was stated as the main reason for calling by 331 respondents. A series of questions was asked regarding level of satisfaction with CIS's performance and how helpful the information provided was in terms of feeling more knowledgeable, making decisions, and taking action. The vast majority of respondents were satisfied with the information received, found it to be helpful, felt more knowledgeable as a result, and would call CIS again with subsequent questions. Although demand characteristics are a possible source of bias, nearly three-quarters of the respondents reported subsequently discussing the information provided with someone else, and almost half sought additional information recommended by CIS. Nearly two-thirds of primary prevention respondents and about half of secondary prevention respondents indicated that they had taken some risk-reducing action subsequent to their interaction with CIS. The CIS is effectively satisfying the information needs of prevention and screening callers; information it is providing is effectively facilitating decisionmaking and stimulating callers to take action.

No abstract

No abstract

Pembrolizumab is an anti-PD-1 humanized monoclonal antibody, standardized therapy for the treatment of metastatic melanoma, providing an overall survival benefit to patients; however, it may be associated with immune-related adverse effects (irAE). We describe the case of a patient with a history of metastatic melanoma undergoing treatment with pembrolizumab, who presented visual acuity deterioration due to inflammatory involvement of the optic nerves. There are few reported cases of an optic neuritis side effect of treatment with immune checkpoint inhibitors. The patient received high doses of steroids and plasmapheresis with improved light perception. This case highlights the need to recognize atypical processes, mediated by the immune system, associated with treatment with immune checkpoint inhibitors (ICI), including pembrolizumab.

La enfermedad de Creutzfeld-Jakob es una patología neurodegenerativa fatal e intratable, que hace parte de las denominadas encefalopatías espongiformes y se produce por la acumulación anormal de la PrP (proteína priónica patogénica),denominada PrPsc, a nivel del sistema nervioso central. La enfermedad priónica humana más común es la forma esporádica de la enfermedad de Creutzfeld-Jakob, cuya aparición se ha relacionado con los efectos ambientales desconocidos o los sucesos aleatorios y genéticos, que resultan en la producción espontánea de PrP en el cerebro. A continuación se presentan dos casos clínicos de dos mujeres que consultan al servicio de urgencias del Hospital Universitario San Ignacio, en quienes se sospechó encefalopatía rápidamente progresiva, compatible con enfermedad de Creutzfeld-Jakob.